(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
4 December 2014 (04.12.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/193935 A1

(51) International Patent Classification:
A61K 38/16 (2006.01) *C07K 14/01* (2006.01)
A61K 47/48 (2006.01) *A61P 25/28* (2006.01)

(21) International Application Number:
PCT/US2014/039760

(22) International Filing Date:
28 May 2014 (28.05.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/828,004 28 May 2013 (28.05.2013) US
61/828,497 29 May 2013 (29.05.2013) US

(71) Applicant: **NEUROPHAGE PHARMACEUTICALS, INC.** [US/US]; 222 Third Street, Suite 3120, Cambridge, MA 02142 (US).

(72) Inventors; and
(71) Applicants : **CARR, Francis, Joseph** [GB/GB]; Birchlea, The Holdings, Balmedie, Aberdeen AB23 8WU (GB). **JONES, Timothy, David** [GB/GB]; 27 Brick Row, Babraham, Cambridge CB22 3AJ (GB).

(72) Inventors: **FISHER, Richard, A.**; 130 Fayerweather Street, Cambridge, MA 02138 (US). **HOLGATE, Robert, George, Edward**; 34 Gower Road, Royston, Hertfordshire SG8 5DU (GB).

(74) Agent: **MCDONELL, Leslie, A.**; Finnegan, Henderson, Farabow, Garrett and Dunner, LLP, 901 New York Avenue NW, Washington, DC 20001 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2014/193935 A1

(54) Title: POLYPEPTIDES COMPRISING A MODIFIED BACTERIOPHAGE G3P AMINO ACID SEQUENCE WITH REDUCED IMMUNOGENICITY

(57) Abstract: The invention relates to polypeptides that comprise a portion of filamentous bacteriophage gene 3 protein (g3p) sufficient to bind to and/or disaggregate amyloid, e.g., the N1-N2 portion of g3p and mutants and fragments thereof, wherein that g3p amino acid sequence has been modified through amino acid substitution to be substantially less immunogenic than the corresponding wild-type g3p amino acid sequence when used in vivo. The polypeptides of the invention retain their ability bind to and/or disaggregate amyloid. The invention relates furthermore to the use of these variant g3p- polypeptides in the treatment and/or prevention of diseases associated with misfolding or aggregation of amyloid.